PNC-27
- Category
- Specialized Research
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
PNC-27 is a synthetic p53-derived peptide marketed as an experimental cancer treatment said to rupture tumor cells while sparing normal ones. The case rests on low-confidence cell and mouse studies (leukemia, ovarian lines), with no human trials and no human safety data. The FDA has warned about contaminated, unapproved versions, and interactions with chemotherapy are unknown. Not an approved drug, it circulates only as unregulated research-grade product.
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.
Overview
PNC-27 is a synthetic 32-amino-acid anti-cancer peptide designed to exploit a specific vulnerability in cancer cells. It combines a fragment of the p53 tumor suppressor protein with a cell-penetrating sequence, creating a molecule that targets HDM-2 -- a protein normally found only inside cells but abnormally displayed on the surface of many cancer types. When PNC-27 binds to surface HDM-2, it assembles into ring-shaped pores (about 35 nm wide) that puncture the cancer cell membrane, causing rapid cell death. Developed at SUNY Downstate Medical Center, it is currently in preclinical development.
How it works in the body
Contains a segment of the p53 tumor suppressor protein linked to a membrane-penetrating sequence. In cancer cells (which overexpress HDM-2 on their surface), PNC-27 binds to HDM-2 and forms pores in the cell membrane, causing the cancer cell to burst. Normal cells don't express surface HDM-2, so they're unaffected.
Research overview
PNC-27 has been tested against more than a dozen cancer cell types -- including pancreatic, breast, melanoma, leukemia, colon, ovarian, and cervical cancers -- and consistently kills cancer cells while leaving normal cells completely unharmed. In mouse models, it has eradicated tumors with no evidence of normal tissue damage. The mechanism was detailed in a 2010 PNAS paper and further characterized through 2025, revealing the membrane pore-forming ("poptosis") mechanism plus a secondary mitochondrial disruption pathway. Key limitations: all studies are preclinical (about 15-20 papers over two decades), the research originates from a single core group of investigators without substantial independent replication, and no human pharmacokinetics or toxicity data exists. NomoCan Pharmaceuticals is pursuing development but no human trials have been registered.
Who researches PNC-27?
Commonly researched by
People researching experimental oncology peptides
Studied for effects on cancer cell targeting or tumor biology in preclinical research.
Important considerations for
Those who are pregnant or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Anyone under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Those with Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Safety & interactions
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
How to read the ratings
- Benefits
- = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
- Risks
- = level of concern: High · Moderate · Low · Theoretical
- Interactions
- = direction with this peptide: Protective / Synergistic · Caution · Neutral
Risk summary(7)
Rated by level of concern
No established human safety profile
HighAbsence of any human trial in the PubMed literature (23 PNC-27 papers, all preclinical or ex vivo); FDA Drug Safety and Availability notice, 1/10/2017
FDA warning — contaminated and unapproved products
HighFDA, 'FDA warns cancer patients not to use PNC-27 products for treatment', 1/10/2017 with 2017 update
Unregulated product quality from research-grade sources
HighFDA notice, 1/10/2017 (lists dosage forms and contamination findings)
Potential for serious adverse events
ModerateFDA notice, 1/10/2017
Possible immunogenicity
TheoreticalNo published PNC-27 immunogenicity studies identified in the PubMed record; general peptide-therapeutic pharmacology
Unknown interactions with chemotherapy and immunotherapy
ModeratePMID 28667027 (Ann Clin Lab Sci 2017) — the only published combination study, and it is preclinical
Contraindicated in pregnancy, lactation, and severe immune disorders
ModerateFDA notice, 1/10/2017; no reproductive toxicology for PNC-27 in the published literature
Interaction summary(6)
Rated by direction with this peptide
Standard-of-care oncology therapy (chemotherapy, radiation, surgery) — risk of substitution or delay
CautionHighThe most consequential real-world interaction is not pharmacologic: FDA explicitly urges cancer patients to discuss treatment with a licensed clinician rather than rely on PNC-27, and using an unproven peptide in place of or in delay of curative-intent therapy is a documented harm pathway.
FDA, 'FDA warns cancer patients not to use PNC-27 products for treatment', 1/10/2017
Immunosuppressants and systemic corticosteroids
CautionModerateFDA named immunocompromised individuals as a higher-risk group for the life-threatening infections possible from bacterially contaminated PNC-27 preparations, so concurrent immunosuppression amplifies the product-quality risk. This is a contamination interaction, not a pharmacologic one.
FDA notice, 1/10/2017 (bacterial contamination findings in marketed PNC-27)
Paclitaxel
SynergisticTheoreticalA single preclinical ovarian cancer study reported synergy between PNC-27 and paclitaxel. The finding is in vitro/ex vivo only, from the originating research group, never replicated, and never tested for additive toxicity in humans — so it is not a basis for combining them.
PMID 28667027, 'Synergy between Paclitaxel and Anti-Cancer Peptide PNC-27 in the Treatment of Ovarian Cancer' (Ann Clin Lab Sci 2017)
Small-molecule MDM2/HDM2 inhibitors (nutlins, idasanutlin, navtemadlin)
CautionTheoreticalPNC-27's active segment is the p53 12-26 MDM-2-binding domain, and nutlin-class drugs occupy the same p53-binding pocket on MDM2, so co-administration could plausibly compete for the target and blunt pore formation. Mechanistically reasonable but never tested in any system.
Mechanism-based inference from PMID 20080680 and PMID 14967026; no combination study exists
Myelosuppressive cytotoxic chemotherapy
CautionTheoreticalOverlapping cytotoxicity and the entirely unknown human toxicity profile of PNC-27 make additive marrow or organ toxicity plausible; no human combination safety data exist in either direction.
No published human combination data; inference from unknown human toxicity profile
Concurrent nebulized or inhaled therapies (in patients using inhaled PNC-27)
CautionLowThe FDA-tested contaminated samples were inhalation solutions, so delivering non-sterile material into the airway carries real pulmonary infection risk, particularly in compromised lungs. This is a route-and-sterility hazard rather than a drug-drug interaction — the other inhaled agent is incidental, so severity is Low as an interaction even though the underlying contamination risk is High on its own.
FDA notice, 1/10/2017 (inhalation solution among the tested dosage forms)
Known risks(7)
No established human safety profile
HighPNC-27 has never been tested in human clinical trials. No human pharmacokinetic, pharmacodynamic, toxicology, immunogenicity, or safety data exist. All safety inferences are extrapolated from preclinical animal studies in immunodeficient nude mice, which do not model the human immune response. The absence of human data means unknown risks including potential systemic toxicity, off-target effects, allergic reactions, and immune responses to a chimeric peptide.
FDA warning — contaminated and unapproved products
HighIn January 2017, the FDA issued a safety communication warning consumers to avoid PNC-27 products marketed as cancer treatments. Testing of an inhalation solution form of PNC-27 revealed bacterial contamination with Variovorax paradoxus and Ralstonia insidiosa. Contaminated injectable or inhalable products can cause severe infections that may result in death, particularly in immunocompromised cancer patients. Products were being sold online in multiple forms (nebulized solution, IV solution, suppositories) without FDA oversight.
Unregulated product quality from research-grade sources
HighUnregulated PNC-27 products sold online are not manufactured under pharmaceutical GMP standards. Purity, identity, sterility, endotoxin levels, and correct peptide sequence cannot be guaranteed. A 32-amino-acid peptide is technically complex to synthesize correctly, and truncated, misfolded, or contaminated products are real risks. Using these products for self-treatment is both illegal and dangerous.
Potential for serious adverse events
Moderate-HighA case report abstract presented at the American College of Gastroenterology (2017) described a patient who experienced massive GI hemorrhage associated with experimental PNC-27 therapy. While the causal relationship is unclear and this is a single case, it highlights the potential for serious adverse events when using an untested compound outside of controlled clinical settings.
Possible immunogenicity
ModeratePNC-27 is a chimeric peptide containing sequences from both human p53 and Drosophila antennapedia protein. The non-human penetratin sequence could potentially trigger immune responses, antibody formation, or allergic reactions upon repeated administration. No immunogenicity studies have been conducted.
Unknown interactions with chemotherapy and immunotherapy
ModeratePNC-27 has been studied with paclitaxel in ovarian cancer cells and mice, with reported synergy. Human interactions with chemotherapy, targeted therapies, immune checkpoint inhibitors, or radiation remain unknown. Using PNC-27 in place of or alongside proven cancer treatments without medical supervision could delay effective treatment and worsen outcomes.
Contraindicated in pregnancy, lactation, and severe immune disorders
ModerateNo reproductive or developmental toxicity studies have been conducted. As an untested anti-cancer peptide that induces cell necrosis, PNC-27 should be assumed unsafe during pregnancy and lactation. Patients with severe autoimmune disorders, immunodeficiency, or those on immunosuppressive therapy face additional unknown risks.
Drug interactions(7)
Immunosuppressants (prednisone, cyclosporine, tacrolimus)
Immunosuppressants may interfere with PNC-27's efficacy. PNC-27's mechanism involves binding to membrane HDM-2 and inducing necrosis, which triggers an inflammatory response and immune-mediated clearance of necrotic debris. Immunosuppression could theoretically impair clearance of dying cancer cells. No interaction studies have been conducted.
Anticoagulants and antiplatelet agents (warfarin, heparin, aspirin, clopidogrel)
PNC-27 induces hemorrhagic necrosis of tumors in vivo. Concurrent use of anticoagulants or antiplatelet agents could theoretically increase the risk of hemorrhagic complications. A case report of massive GI hemorrhage associated with experimental PNC-27 therapy has been described. Extreme caution would be warranted.
Chemotherapy agents (all classes)
PNC-27 has not been studied in combination with any chemotherapy agent. The interaction profile is completely unknown. PNC-27 works through a mechanism (membrane pore formation) that is independent of traditional chemotherapy pathways, so additive or synergistic effects are theoretically possible but unproven. Oncologist supervision would be essential for any combination use.
Immune checkpoint inhibitors (pembrolizumab, nivolumab, ipilimumab)
PNC-27 induces necrotic (not apoptotic) cell death, which releases intracellular contents and may stimulate immune responses. Combining with checkpoint inhibitors could theoretically enhance anti-tumor immunity through immunogenic cell death, but could also increase inflammation-related toxicity. No studies exist.
HDM-2/MDM2 inhibitors (nutlin-3, idasanutlin, milademetan)
MDM2 inhibitors target the same HDM-2 protein as PNC-27, but intracellularly rather than at the membrane. Theoretical redundancy in mechanism could occur. MDM2 inhibitors block the intracellular HDM-2-p53 interaction to stabilize p53, while PNC-27 targets membrane-associated HDM-2. Whether combining them would be additive or interfere with each other is unknown.
PNC-28 (related anti-cancer peptide)
PNC-28 shares a similar mechanism of action, targeting membrane HDM-2 through a slightly different p53 fragment (residues 17-26). Combined use would be mechanistically redundant and has not been studied. No clear rationale for combining both peptides exists.
High-dose antioxidant supplements
Theoretical concern that megadose antioxidants could interfere with the oxidative stress component of PNC-27's mitochondrial disruption mechanism. The primary pore-formation mechanism would likely be unaffected, but the secondary mitochondrial disruption pathway could theoretically be attenuated.
Research & benefits
Evidence base
- Evidence Level
- Preclinical
- Total Studies
- 12
- Human Studies
- 0
PNC-27 has strong preclinical data demonstrating selective cancer cell killing through a novel mechanism (binding to membrane-bound HDM-2 and inducing transmembrane pore formation). The mechanism is well-characterized at the structural, biochemical, and cellular levels. In vitro efficacy has been shown in pancreatic cancer, breast cancer, melanoma, multiple leukemia subtypes, colon cancer (including cancer stem cells), patient-derived ovarian cancer (including chemotherapy-resistant lines), and cervical cancer. In vivo results in nude mice show tumor eradication without normal tissue damage. However, translation to humans remains entirely theoretical. No human clinical trials have been conducted, no IND has been filed with the FDA, and the FDA has issued warnings against using PNC-27 products marketed as cancer treatments. The lack of human pharmacokinetics, biodistribution, immunogenicity, and systemic safety data represents a critical gap that must be addressed before clinical application.
Researched for(7)
Rated by confidence in the evidence
Selective cancer cell killing via membrane-bound HDM-2 targeting
LowSelective killing shown in vitro across many cancer types; mechanism defined, no human trials yet.
PMID 20080680 (Sarafraz-Yazdi et al., Proc Natl Acad Sci U S A 2010); PMID 35625682 (Biomedicines 2022); PMID 14967026 (Biochemistry 2004, NMR structure of the p53 12-26 MDM-2-binding peptide)
Transmembrane pore formation causing rapid necrotic cancer cell death
LowCell-culture studies show rapid pore-based cell death within hours; mechanism not yet confirmed independently.
PMID 35625682 (Biomedicines 2022); PMID 38927351 (Biomedicines 2024, 'Poptosis' review); PMID 20182728 (Cancer Chemother Pharmacol 2010)
Efficacy against leukemia cells with no harm to normal hematopoietic cells
LowLab and mouse studies show leukemia cell death while sparing normal blood cells; no human trials.
PMID 32878773 (Anticancer Res 2020); PMID 31337857 (Leukemia 2020, membrane HDM2 targeting in AML); PMID 25117093 (Ann Clin Lab Sci 2014); PMID 38927351 (Biomedicines 2024)
Efficacy against patient-derived ovarian cancer including chemotherapy-resistant cells
SpeculativeOne ex vivo study on patient tumor tissue, not independently replicated; not clinical trial evidence.
PMID 26663795 (Ann Clin Lab Sci 2015); PMID 28667027 (Ann Clin Lab Sci 2017); PMID 33067207 (Ann Clin Lab Sci 2020, ovarian cancer cell lines)
In vivo tumor eradication in nude mice without normal tissue damage
LowTumor regression seen in mouse xenograft models across several cancer types; not evidence of a cure.
PMID 38927351 (Biomedicines 2024); PMID 33419797 (Anticancer Res 2021, colon cancer); PMID 31337857 (Leukemia 2020, AML xenografts)
Secondary mitochondrial disruption mechanism in cancer cells
SpeculativeOne preliminary study reports a secondary mitochondrial effect in one pancreatic cancer cell line.
PMID 38802154 (Ann Clin Lab Sci 2024) — supports the plasma-membrane mechanism directly; the mitochondrial element is secondary within it
Selective efficacy against cervical cancer cells
SpeculativeOne 2025 lab-dish study reports selective cervical cancer cell killing; not independently replicated.
PMID 40750238 (Ann Clin Lab Sci 2025)
Benefits(7)
Selective cancer cell killing via membrane-bound HDM-2 targeting
Sarafraz-Yazdi et al. 2010 (PNAS, PMID 20080680) — PNC-27 kills cancer cells (MIA-PaCa-2 pancreatic, MCF-7 breast, A-2058 melanoma, TUC-3 pancreatic acinar) by binding to HDM-2 in their membranes. HDM-2 levels were 4-9 fold higher in cancer cell membranes than normal cells. Untransformed cells (MCF-10-2A, BMRPA1, AG13145 fibroblasts) were completely unaffected. When normal MCF-10-2A cells were transfected to express membrane-localized HDM-2, they became susceptible to PNC-27, confirming the specificity of the mechanism.
Transmembrane pore formation causing rapid necrotic cancer cell death
Sarafraz-Yazdi et al. 2022 (Biomedicines, PMID 35625682) — High-resolution electron microscopy directly imaged PNC-27-induced transmembrane pores in cancer cell membranes, measuring 28-44 nm internal diameter (average 34.5 nm). Pores were lined with PNC-27-HDM-2 complexes identified through immunogold labeling. The mechanism involves temperature-independent binding at 17 degrees C and temperature-dependent pore assembly at 37 degrees C. Cell death is necrotic (not apoptotic), independent of intracellular signaling, p53 status, or MDR gene products.
Efficacy against leukemia cells with no harm to normal hematopoietic cells
Davitt et al. 2014 (Annals of Clinical and Laboratory Science, PMID 25117093) — PNC-27 induced nearly 100% cell killing of K562 leukemia cells with LDH release while having no effect on normal lymphocyte controls. Thadi et al. 2020 (Anticancer Research, PMID 32878773) — PNC-27 induced necrosis and LDH release within 4 hours in U937, OCI-AML3, and HL-60 acute myeloid leukemia cell lines while sparing normal hematopoietic cells.
Efficacy against patient-derived ovarian cancer including chemotherapy-resistant cells
Sarafraz-Yazdi et al. 2015 (Annals of Clinical and Laboratory Science, PMID 26663795) — PNC-27 demonstrated dose-dependent cytotoxicity against freshly isolated primary human ovarian cancer cells from mucinous cystadenocarcinoma and high-grade papillary serous carcinoma. Critically, PNC-27 was also cytotoxic to long-established, chemotherapy-resistant human ovarian cancer cell lines. The negative control peptide PNC-29 had no effect, confirming specificity.
In vivo tumor eradication in nude mice without normal tissue damage
Thadi et al. 2021 (Anticancer Research, DOI 10.21873/anticanres.14749) — In a murine peritoneal carcinomatosis model, PNC-27 (100 mcg/g body weight, intraperitoneal, 14 days) caused widespread hemorrhagic necrosis of CT-26 colon cancer tumors while histological analysis confirmed no damage to surrounding normal peritoneal tissues. PNC-27 also selectively killed CD44+ colon cancer stem cells. Mice treated with PNC-27 showed significant tumor regression and extended survival compared to PNC-29 (inactive control peptide) treated mice.
Secondary mitochondrial disruption mechanism in cancer cells
Krzesaj et al. 2024 (Annals of Clinical Laboratory Science, PMID 38802154) — Following cellular entry into MIA-PaCa-2 pancreatic cancer cells, PNC-27 localizes to mitochondrial membranes and causes functional mitochondrial failure. Treated cancer cell mitochondria fail to retain mitotracker dye while other organelles remain functional. Immuno-electron microscopy confirmed PNC-27 presence on mitochondrial membranes. This dual mechanism (membrane pore formation + mitochondrial disruption) provides redundant cancer cell killing pathways.
Selective efficacy against cervical cancer cells
Krzesaj et al. 2025 (Annals of Clinical and Laboratory Science, PMID 40750238) — PNC-27 demonstrated cytotoxicity against HTB-35 cervical cancer cells at an IC50 of 12.4 micromolar with no effect on normal PCS-480 cervical epithelial cells. HTB-35 cancer cells expressed high levels of HDM-2 in their membranes while normal cervical cells did not. HDM-2 expression remained stable in both culture media and alcoholic preservative solutions.
Key studies(9)
Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes
In vitro experimental study (structural biology, cell biology, biochemistry)Multiple cancer and normal cell lines (MIA-PaCa-2, MCF-7, A-2058, TUC-3, MCF-10-2A, BMRPA1, AG13145)Acute treatment experimentsSarafraz-Yazdi E, Bowne WB, Adler V, Sookraj KA, Wu V, Shteyler V, Patel H, Oxbury W, Brandt-Rauf P, Zenilman ME, Michl J, Pincus MR
Proceedings of the National Academy of Sciences (PNAS)
2010
PNC-27 adopts an HDM-2-binding conformation with its 3D structure superimposing precisely on the x-ray crystallographic structure of p53 bound to HDM-2. Cancer cell membranes expressed 4-9 fold higher HDM-2 levels than normal cells. PNC-27 co-localized with membrane HDM-2 in cancer cells and induced membranolysis. Transfection of membrane-localized HDM-2 into normal MCF-10-2A cells rendered them susceptible to PNC-27, confirming HDM-2 membrane expression as the sole determinant of selectivity.
PNC-27, a Chimeric p53-Penetratin Peptide Binds to HDM-2 in a p53 Peptide-like Structure, Induces Selective Membrane-Pore Formation and Leads to Cancer Cell Lysis
Experimental research (computational modeling, electron microscopy, immunofluorescence, cytotoxicity assays)Multiple cancer and normal cell linesAcute treatment experimentsSarafraz-Yazdi E, Mumin S, Cheung D, Fridman D, Lin B, Wong L, Rosal R, Rudolph R, Frenkel M, Thadi A, Morano WF, Bowne WB, Pincus MR, Michl J
Biomedicines
2022
PNC-27 binds HDM-2 with approximately 1:1 stoichiometry. High-resolution transmission and scanning electron microscopy directly imaged transmembrane pores of 28-44 nm internal diameter (average 34.5 nm) lined with PNC-27-HDM-2 complexes (identified by immunogold labeling). Pore structures protruded 8-10 nm beyond the cell surface. Mechanism involves temperature-independent binding and temperature-dependent pore assembly. Cancer cell death was necrotic, rapid, and independent of intracellular signaling pathways or p53 status.
The anti-cancer peptide, PNC-27, induces tumor cell lysis as the intact peptide
In vitro experimental studyMCF-7 cancer cells and MCF-10-2A normal cellsAcute treatment (30 min observations)Sookraj KA, Bowne WB, Adler V, Sarafraz-Yazdi E, Michl J, Pincus MR
Cancer Chemotherapy and Pharmacology
2010
PNC-27 induces cancer cell membrane lysis by acting as the intact whole peptide, not through fragmentation. In cancer cells (MCF-7), increasing punctate yellow fluorescence indicated intact peptide binding and accumulating in membranes during cell death. In normal cells (MCF-10-2A), initial uniform fluorescence disappeared without cell death, demonstrating the peptide does not persist in normal cell membranes.
The anti-cancer peptide, PNC-27, induces tumor cell necrosis of a poorly differentiated non-solid tissue human leukemia cell line that depends on expression of HDM-2 in the plasma membrane of these cells
In vitro experimental studyK562 leukemia cells and normal lymphocyte controlsAcute treatment experimentsDavitt K, Babcock BD, Fenelus M, Poon CK, Sarkar A, Trivigno V, Zolkind PA, Matthew SM, Grin'kina N, Orynbayeva Z, Shaikh MF, Adler V, Michl J, Sarafraz-Yazdi E, Pincus MR, Bowne WB
Annals of Clinical and Laboratory Science
2014
K562 leukemia cells strongly express HDM-2 in their membranes. PNC-27 co-localizes with membrane HDM-2 and induces nearly 100% cell killing with LDH release, while having no effect on normal lymphocyte control cells. Cell death occurs through transmembrane pore formation and necrosis, independent of p53 activity. This was the first demonstration of PNC-27 efficacy against a non-solid tissue (hematologic) cancer.
Targeting Membrane HDM-2 by PNC-27 Induces Necrosis in Leukemia Cells But Not in Normal Hematopoietic Cells
In vitro experimental studyU937, OCI-AML3, and HL-60 AML cell lines plus normal hematopoietic cells4-hour acute treatmentThadi A, Lewis L, Goldstein E, Aggarwal A, Khalili M, Steele L, Polyak B, Seydafkan S, Bluth MH, Ward KA, Styler M, Campbell PM, Pincus MR, Bowne WB
Anticancer Research
2020
HDM-2 is expressed at high levels in the membranes of three acute myeloid leukemia cell lines (U937, OCI-AML3, HL-60). PNC-27 induced cell necrosis and LDH release within 4 hours in all three AML cell lines while sparing normal hematopoietic cells. The authors propose that targeting membrane HDM-2 can be a potential strategy to treat leukemia.
Ex vivo Efficacy of Anti-Cancer Drug PNC-27 in the Treatment of Patient-Derived Epithelial Ovarian Cancer
Ex vivo experimental study (patient-derived cancer cells)Primary cultures from 2 patients (mucinous cystadenocarcinoma, high-grade papillary serous carcinoma) plus established chemotherapy-resistant cell linesDose-response experimentsSarafraz-Yazdi E, Gorelick C, Wagreich AR, Salame G, Angert M, Gartman CH, Gupta V, Bowne WB, Lee YC, Abulafia O, Pincus MR, Michl J
Annals of Clinical and Laboratory Science
2015
PNC-27 inhibited growth and was cytotoxic in a dose-dependent manner to freshly isolated primary human ovarian cancer cells — the first demonstration of efficacy on patient-derived primary cancer cells. PNC-27 was also cytotoxic to long-established, chemotherapy-resistant ovarian cancer cell lines. Control peptide PNC-29 had no effect, confirming specificity. The authors concluded PNC-27 has potential as an alternative treatment for both untreated and chemotherapy-resistant ovarian cancers.
Molecular Targeting of H/MDM-2 Oncoprotein in Human Colon Cancer Cells and Stem-like Colonic Epithelial-derived Progenitor Cells
In vitro and in vivo experimental studySix colon cancer cell lines (including CD44+ cancer stem cells) in vitro; CT-26 peritoneal carcinomatosis model in nude mice in vivo14-day treatment (in vivo)Thadi A, Morano WF, Khalili M, Babcock BD, Shaikh MF, Foster DS, Piazza Y, Gleeson EM, Goldstein E, Steele L, Campbell PM, Lin B, Pincus MR, Bowne WB
Anticancer Research
2021
PNC-27 showed dose-dependent cytotoxicity against six colon cancer cell lines including CD44+ cancer stem cells while the normal control cell line remained unaffected. Cell death was necrotic (high LDH release, no caspase-3 activation). In vivo, PNC-27 (100 mcg/g body weight, intraperitoneal, 14 days) induced widespread hemorrhagic necrosis of peritoneal colon cancer tumor nodules with no damage to normal tissues. Mice treated with PNC-27 showed significant tumor regression and extended survival versus PNC-29 control.
Anti-Cancer Peptide PNC-27 Kills Cancer Cells by Unique Interactions with Plasma Membrane-Bound hdm-2 and with Mitochondrial Membranes Causing Mitochondrial Disruption
In vitro experimental study (mechanism of action)MIA-PaCa-2 human pancreatic cancer cellsAcute treatment experimentsKrzesaj P, Adler V, Feinman RD, Miller A, Silberstein M, Yazdi E, Pincus MR
Annals of Clinical Laboratory Science
2024
PNC-27 operates through a dual mechanism: (1) binding to membrane-bound HDM-2 to form transmembrane pores, and (2) entering cancer cells and localizing to mitochondrial membranes, causing mitochondrial disruption. Mitochondria in treated cells fail to retain mitotracker dye while other organelles remain functional. Immuno-electron microscopy confirmed PNC-27 presence on mitochondrial membranes. Antibody-blocking experiments validated HDM-2 interaction specificity.
HDM-2-Targeting Peptide PNC-27 Kills Cervical Cancer Cells but not Normal Cervical Cells
In vitro experimental studyHTB-35 cervical cancer cells and PCS-480 normal cervical epithelial cellsDose-response experimentsKrzesaj PK, Seydafkan S, and others (SUNY Health Sciences, NYU Langone, Mirimus, Drexel)
Annals of Clinical and Laboratory Science
2025
PNC-27 was cytotoxic to HTB-35 cervical cancer cells at an IC50 of 12.4 micromolar with no effect on normal PCS-480 cervical epithelial cells. HTB-35 cancer cells expressed high levels of HDM-2 in their membranes while normal cervical cells did not. HDM-2 expression remained stable in both culture media and alcoholic preservative solutions. The authors concluded PNC-27 may be an effective drug against cervical cancer.
Regulation & availability
Why researchers look at it
Exploits a target most cancer cells display but normal cells lack (surface HDM-2), killing over a dozen cancer types in preclinical testing while leaving normal cells unharmed — and its membrane pore-forming mechanism bypasses common chemo resistance. Evidence includes work from the developing research group and independent preclinical investigators, with no established human trial evidence, and the FDA has warned against PNC-27 products marketed as cancer treatments.
- FDA status
- NOT FDA-APPROVED. The FDA has never approved PNC-27 for any indication. No IND (Investigational New Drug application), NDA (New Drug Application), or BLA (Biologics License Application) has been filed with the FDA for PNC-27. It is not listed in the FDA Orange Book or the National Drug Code (NDC) directory. No clinical trials for PNC-27 are registered on ClinicalTrials.gov. In January 2017, the FDA issued a safety communication explicitly warning consumers to avoid PNC-27 products being marketed online as cancer treatments. The FDA found that tested samples of an inhalation solution form of PNC-27 were contaminated with bacteria (Variovorax paradoxus in initial testing, Ralstonia insidiosa in follow-up testing). The FDA stated that PNC-27 has not been evaluated for safety or effectiveness, that the products are unapproved new drugs marketed in violation of federal law, and that consumers should discuss approved treatment options with their healthcare providers. The product had gained visibility after appearing in a TEDx talk and was being marketed in multiple forms (nebulized solution, IV solution, suppositories) through websites directing patients to foreign doctors for treatment.
- WADA status
- PROHIBITED UNDER S0 when used as an unapproved pharmacological substance. PNC-27 is not individually named, but S0 covers unapproved pharmacological substances not addressed elsewhere on the List. Its experimental anticancer purpose does not provide an exemption.
- Prescribability
- No — PNC-27 is not FDA-approved and is not prescribable through any standard medical channel worldwide. It has never undergone human clinical trials and has no established human safety or efficacy data. In January 2017, the FDA issued an explicit warning to consumers to avoid PNC-27 products marketed as cancer treatments, noting that they are unapproved, lack established safety data, and that tested samples were found to be contaminated with bacteria (Variovorax paradoxus and Ralstonia insidiosa). A physician cannot legally prescribe PNC-27 for cancer treatment in the US, and using it outside of a properly designed research protocol carries significant legal and safety risks.
- Availability
- PNC-27 is NOT available as an approved pharmaceutical or supplement through any legitimate medical channel. Some clinics outside the United States have reportedly offered unapproved PNC-27 treatments in forms including nebulized inhalation solutions, intravenous solutions, vaginal suppositories, and rectal suppositories. These are not sanctioned by any regulatory authority, and the FDA found bacterial contamination (Variovorax paradoxus and Ralstonia insidiosa) in tested inhalation solution samples. NomoCan Pharmaceuticals LLC is the entity associated with PNC-27's development, though no commercial drug product has been brought to market. PNC-27 is not available through US or EU pharmacies, not listed in any pharmacopeia, and cannot be obtained through prescription channels. The FDA has explicitly warned consumers against using PNC-27 products marketed as cancer treatments.
International status
EU
Not approved
US
Not FDA-approved
Worldwide
No regulatory approval in any jurisdiction
Regulatory timeline(15)
- ~2000PNC-27 is designed and synthesized at SUNY Downstate Medical Center by Matthew R. Pincus and collaborators using computational supercomputer modeling to create a chimeric p53-penetratin peptide targeting HDM-2.
- 2006Early studies demonstrate PNC-27 and PNC-28 selectively kill cancer cells by membrane pore formation. Abstract presented at AACR (American Association for Cancer Research).
- 2010-02Landmark PNAS paper (Sarafraz-Yazdi et al.) establishes that PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding HDM-2 in their membranes (PMID 20080680). Cancer cell membranes shown to express 4-9 fold more HDM-2 than normal cells.
- 2010-07Sookraj et al. publish in Cancer Chemotherapy and Pharmacology showing PNC-27 induces tumor cell lysis as the intact peptide (PMID 20182728).
- 2014Davitt et al. extend PNC-27 efficacy to non-solid tumors, demonstrating near-100% killing of K562 leukemia cells with no effect on normal lymphocytes (PMID 25117093).
- 2015Sarafraz-Yazdi et al. demonstrate ex vivo efficacy against patient-derived primary ovarian cancer cells, including chemotherapy-resistant lines — first use on freshly isolated human cancer cells (PMID 26663795).
- 2017-01FDA issues safety communication warning consumers to avoid PNC-27 products marketed as cancer treatments.
- 2017-10Case report abstract at American College of Gastroenterology describes massive GI hemorrhage associated with experimental PNC-27 therapy.
- 2020-09Thadi et al. confirm PNC-27 induces necrosis in three AML cell lines (U937, OCI-AML3, HL-60) while sparing normal hematopoietic cells (PMID 32878773).
- 2021-01Thadi et al. publish in vivo colon cancer study showing PNC-27 causes hemorrhagic necrosis of peritoneal tumor nodules in nude mice with no normal tissue damage, and selectively kills CD44+ cancer stem cells (DOI 10.21873/anticanres.14749).
- 2022-04Sarafraz-Yazdi et al. publish high-resolution imaging of PNC-27 transmembrane pores (28-44 nm diameter) in Biomedicines, with immunogold labeling confirming PNC-27-HDM-2 complexes lining the pores (PMID 35625682).
- 2022-02Independent group publishes use of PNC-27 as a targeting ligand on nanoparticle drug delivery systems (SWCNT) for colon adenocarcinoma in vivo, validating PNC-27's cancer-targeting capability in a nanotechnology context (ScienceDirect).
- 2024-03Krzesaj et al. discover secondary mitochondrial disruption mechanism — PNC-27 enters cancer cells and damages mitochondrial membranes in addition to forming plasma membrane pores (PMID 38802154).
- 2025-05Krzesaj et al. demonstrate PNC-27 efficacy against cervical cancer cells (HTB-35, IC50 12.4 micromolar) with no effect on normal cervical cells (PMID 40750238).
- 2026-03PNC-27 remains without FDA approval, IND filing, or registered clinical trials. No human safety or efficacy data exists. Available only as a research reagent. Active preclinical research continues from the Pincus/Bowne group.
Sources & FAQs
Research sources(14)
- Sarafraz-Yazdi et al. 2010 — PNC-27 HDM-2 binding and cancer selectivity (PNAS)
- Sarafraz-Yazdi et al. 2022 — PNC-27 pore formation and structure (Biomedicines)
- Sookraj et al. 2010 — PNC-27 tumor cell lysis as intact peptide
- Davitt et al. 2014 — PNC-27 kills leukemia K562 cells
- Thadi et al. 2020 — PNC-27 necrosis in AML cells, not normal hematopoietic cells
- Sarafraz-Yazdi et al. 2015 — PNC-27 ex vivo ovarian cancer efficacy
- Thadi et al. 2021 — PNC-27 colon cancer and cancer stem cells, in vivo
- Krzesaj et al. 2024 — PNC-27 mitochondrial disruption mechanism
- Krzesaj et al. 2025 — PNC-27 kills cervical cancer cells
- FDA — Warning to consumers about PNC-27 (January 2017)
- Pharmacy Times — FDA warning on PNC-27 contamination
- PNAS full text — PNC-27 mechanism (PMC2836618)
- Biomedicines full text — PNC-27 pore formation (PMC9138867)
- WADA 2026 Prohibited List
Frequently asked questions(6)
How does PNC-27 selectively target cancer cells without harming normal cells?
PNC-27 exploits a cancer-specific molecular vulnerability: the abnormal expression of HDM-2 (human double minute 2) protein on the outer surface of cancer cell membranes. In normal cells, HDM-2 is located exclusively inside the cell (nucleus/cytoplasm) where it regulates p53. In cancer cells, HDM-2 is aberrantly expressed on the plasma membrane surface at levels 4-9 fold higher than in normal cells. PNC-27 contains the p53 domain (residues 12-26) that binds HDM-2, so it binds specifically to this membrane-associated HDM-2 on cancer cells, oligomerizes into ring structures, and forms transmembrane pores that cause necrotic cell death. Normal cells lack membrane HDM-2 and are completely unaffected. This has been confirmed by transfecting normal cells with membrane-localized HDM-2, which rendered them susceptible to PNC-27 (Sarafraz-Yazdi et al. 2010 PNAS).
Has PNC-27 been tested in humans?
No. As of March 2026, PNC-27 has never been tested in any human clinical trial. All published evidence is preclinical: in vitro cell culture studies, ex vivo studies on patient-derived cancer cells, and in vivo studies in immunodeficient nude mice. No human pharmacokinetic, safety, dose-finding, or efficacy data exist. No clinical trials for PNC-27 are registered on ClinicalTrials.gov. The FDA has explicitly warned against using PNC-27 products marketed as cancer treatments.
What types of cancer has PNC-27 been tested against?
In preclinical studies, PNC-27 has demonstrated selective cytotoxicity against: pancreatic cancer (MIA-PaCa-2, TUC-3), breast cancer (MCF-7), melanoma (A-2058), chronic myelogenous leukemia (K562), acute myeloid leukemia (U937, OCI-AML3, HL-60), colon cancer (CT-26, HCT-116, SW-480, HT-29, including CD44+ cancer stem cells), ovarian cancer (patient-derived mucinous cystadenocarcinoma, papillary serous carcinoma, and chemotherapy-resistant lines), and cervical cancer (HTB-35). The selectivity appears to depend on membrane HDM-2 expression rather than cancer type, suggesting potential broad-spectrum activity, though this has not been confirmed in human patients.
Why hasn't PNC-27 entered clinical trials despite decades of research?
Several factors likely contribute: (1) The research has been conducted by a relatively small academic group without major pharmaceutical industry backing or large-scale funding required for clinical development; (2) Manufacturing GMP-grade peptide at clinical scale for a 32-amino-acid peptide is technically challenging and expensive; (3) Peptide therapeutics face inherent pharmacokinetic challenges including rapid clearance, potential immunogenicity, and limited systemic bioavailability; (4) The FDA warning in 2017 regarding contaminated PNC-27 products may have complicated the regulatory pathway; (5) Preclinical development requirements (IND-enabling toxicology, pharmacokinetics, GMP manufacturing) are resource-intensive. NomoCan Pharmaceuticals LLC is associated with the development effort, but the status of any formal clinical development program is unclear.
Is PNC-27 safe to use?
The safety of PNC-27 in humans has NOT been established. No human safety data exists. In preclinical studies, PNC-27 showed no toxicity to normal cells in vitro or to normal tissues in nude mice in vivo. However, (1) the FDA found bacterial contamination in PNC-27 products marketed to consumers; (2) no formal toxicology, pharmacokinetic, or immunogenicity studies have been published; (3) a case report abstract from the American College of Gastroenterology (2017) described a patient who experienced massive GI hemorrhage associated with experimental PNC-27 therapy; (4) research-grade peptides are not manufactured under GMP standards and may contain impurities. The FDA explicitly warns against using PNC-27 products for cancer treatment.
What is the difference between PNC-27 and PNC-28?
PNC-27 and PNC-28 are related anti-cancer peptides from the same research group. PNC-27 contains p53 residues 12-26 (the HDM-2 binding domain) fused to the penetratin membrane-penetrating sequence. PNC-28 contains p53 residues 17-26 fused to a membrane residency peptide (MRP). Both target membrane-bound HDM-2 and induce transmembrane pore formation in cancer cells, but they differ in their specific p53 fragment and may have different binding kinetics and potency. PNC-28 has also been shown to block pancreatic cancer cell growth in vivo (Sookraj et al. 2008, PMID 16688716). Both peptides are highly selective for cancer cells and share the same fundamental mechanism of action.